Our Story

OUR DNA

LNC is working on the first gut modulator project initiated by medical nutrition product clinical outcomes

Obesity management to date

+ learn more

Three therapeutic strategies currently predominate with respect to obesity management: nutritional approaches, drugs and bariatric surgery.
Despite the results obtained, they all have limitations: low level of credibility, safety issues, moderate efficacy, no fat loss specificity, weight regain phenomenon, underlying causes not addressed.

FAT LOSS SPECIFICITY

It is well established that lean mass preservation is a long-term maintenance factor on weight and metabolism.

We cannot evaluate efficacy of therapeutic strategy only on weight loss. Considering the preservation of lean body mass and so the fat mass specificity is a mandatory.

From the creation of LNC, the founders, previously managers in the pharmaceutical industry, shared the same vision:
to address the issue of obesity and cardiometabolic disorders
by acting on its root causes

OUR APPROACH

Thanks to this ambition and by implementing a truly patient- focused approach, LNC was able to develop and clinically assess a medical nutrition product called Stablor between 2011 and 2015.

+ learn more

why medical nutrition ?

Obesity is a multicomponent disease and overweight/obese patient have specific metabolic impairments and nutritional deficiencies.

The deep understanding of the physiopathology leads LNC to develop Medical Food: Only Medical Food have the capability to address underlying causes instead of consequences of the disease with a safe and efficient profile.

The rise of microbiome

The same four-year period saw major growth in research on the impact of the microbiota on health (4,500 publications in PubMed versus 635 in 2005-2009).

+ learn more

PHYSIOPATHOLOGY OF OVERWEIGHT/OBESE PATIENT PRESENTING ABDOMINAL OBESITY AND ASSOCIATED RISK FACTORS.

Inadequate lifestyle = Sedentarity, poor diet (quality+quantity), genetic

GUT IMPAIRMENTS

  • Microbiome dysbiosis
  • Gut permeability
  • Inflammation

CHRONIC METABOLIC IMPAIRMENTS AND NUTRITIONAL DEFICIENCES

  • Inflammation
  • Insulin-resistance
  • Lipid metabolism dysregulation (dyslipidemia)
  • Nutrients deficiencies

16082836958_ce185429b8_o

The close collaboration that has developed LNC with the international research community led the company to look more closely at this promising field.

Intestinal microbiota plays a vital role in obesity.

Thus in 2014, LNC initiated an ancillary study to the international clinical trial being carried out on Stablor. It was designed to determine the impact of this product on the human microbiota.

Publications

In order to be on the cutting edge of scientific research and innovation, we select and analyse key scientific publications and materials

Discover our selection

Find out more
The strong protective role of...
Variation in the human fecal microbiota has previously been associated with body mass index (BMI)....
C.minuta is the species related...
Host genetics and the gut microbiome can both influence metabolic phenotypes. Here, Goodrich et al....
What is the link between...
Evidence suggests the gut microbiome is involved in the development of cardiovascular disease (CVD),...